The Moderna Inc (NASDAQ:MRNA) stock and those of its competitors have come under immense pressure recently after the United States trade envoy Katherine Tai expressed her support for a World Trade Organisation proposal for lifting intellectual property right on CAVID 19 vaccines.
However, there are some factors that investors need to consider before making any decision about the Moderna stock. First of all, the COVID 19 is not an extraordinary situation considering the fact that similar deadly viruses have wreaked havoc at different points in history as well.
On the other hand, it is also necessary to keep in mind that vaccines of this nature are pretty hard to make. The company had to build customized machines for developing its vaccine and it is going to be difficult for other companies to come up with similar systems. Lastly, the company has plenty of time to sell its vaccines. In Q1 2021, Moderna sold 102 million doses that worked out to revenues of $1.7 billion and in the second quarter, it is going to more than double that number.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.